Risedronic acid Other names: Risedronate sodium

Chemical formula: C₇H₁₁NO₇P₂ Molecular mass: 283.112 g/mol PubChem compound: 5245

Interactions

Risedronic acid interacts in the following cases:

History of oesophageal disorders, inability to stand upright, upper gastrointestinal problems

Bisphosphonates have been associated with oesophagitis, gastritis, oesophageal ulcerations and gastroduodenal ulcerations. Thus, caution should be used:

In patients who have a history of oesophageal disorders which delay oesophageal transit or emptying e.g. stricture or achalasia.
In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet.
If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett’s oesophagus).

Pregnancy

There are no adequate data from the use of risedronate sodium in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.

Risedronate sodium must not be used during pregnancy.

Nursing mothers

Studies in animal indicate that a small amount of risedronate sodium pass into breast milk. Risedronate sodium must not be used by breast-feeding women.

Effects on ability to drive and use machines

Risedronate sodium has no or negligible influence on the ability to drive and use machines.

< Previous: Usage

Next: Pharmacology >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.